American Association of Individual Investors2d
Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Up 31.29%
Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 31.29%, which has investors questioning if this is right time to sell.
Medical Xpress on MSN8d
Can a heart failure drug effectively treat a lethal form of ovarian cancer? Scientists hope the answer is 'yes'
Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...
Unlocking new insights into hereditary ovarian cancer risk
Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...
casereports.bmj9d
Non-bacterial thrombotic endocarditis in a patient with high-grade serous ovarian carcinoma: diagnostic challenges and management insights
A biopsy of the pelvic mass and analysis of ascitic fluid was consistent with high-grade serous carcinoma of tubo-ovarian origin. Following discussion at the gynaecology multidisciplinary team meeting ...
Wedbush Expects Higher Earnings for Zentalis Pharmaceuticals
Equities research analysts at Wedbush boosted their FY2024 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Wedbush analyst R.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $10.00 Price Target at HC Wainwright
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price target lowered by HC Wainwright from $20.00 to $10.00 in a research report released on Wednesday,Benzinga reports. The firm currently ...
Pharmabiz17d
European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer
European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...